Evoke Pharma EBITDA Margin 2012-2024 | EVOK

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Evoke Pharma (EVOK) over the last 10 years. The current EBITDA margin for Evoke Pharma as of June 30, 2024 is .
Evoke Pharma EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-06-30 $0.01B $-0.01B -77.78%
2024-03-31 $0.01B $-0.01B -114.29%
2023-12-31 $0.01B $-0.01B -133.33%
2023-09-30 $0.01B $-0.01B -160.00%
2023-06-30 $0.00B $-0.01B -200.00%
2023-03-31 $0.00B $-0.01B -266.67%
2022-12-31 $0.00B $-0.01B -400.00%
2022-09-30 $0.00B $-0.01B -800.00%
2022-06-30 $0.00B $-0.01B -800.00%
2022-03-31 $0.00B $-0.01B -800.00%
2021-12-31 $0.00B $-0.01B -900.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Teligent (TLGT) United States $0.000B 0.00